---
title: "BOJI CRO released its first-quarter performance, with a net profit attributable to the parent company of 3.9006 million yuan, a decrease of 76.38%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237593898.md"
description: "BOJI CRO released its Q1 2025 performance, with operating revenue of 139 million yuan, a year-on-year decrease of 17.06%; net profit attributable to the parent company of 3.9006 million yuan, a year-on-year decline of 76.38%; net profit excluding non-recurring gains and losses of 1.6979 million yuan, a year-on-year decrease of 88.28%; basic earnings per share of 0.0102 yuan"
datetime: "2025-04-25T14:24:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237593898.md)
  - [en](https://longbridge.com/en/news/237593898.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237593898.md)
generator: "portal-rs"
---

# BOJI CRO released its first-quarter performance, with a net profit attributable to the parent company of 3.9006 million yuan, a decrease of 76.38%

According to the Zhitong Finance APP, BOJI CRO (300404.SZ) released its first-quarter report for 2025, with operating revenue of 139 million yuan, a year-on-year decrease of 17.06%. The net profit attributable to shareholders of the listed company was 3.9006 million yuan, a year-on-year decrease of 76.38%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.6979 million yuan, a year-on-year decrease of 88.28%. The basic earnings per share were 0.0102 yuan

### Related Stocks

- [300404.CN](https://longbridge.com/en/quote/300404.CN.md)

## Related News & Research

- [Innova Captab Revises FY26 Accounts and Clears Baddi Plant Expansion](https://longbridge.com/en/news/296661728.md)
- [Innventure directors force management, board to forfeit Accelsius earnout shares tied to DarkNX order](https://longbridge.com/en/news/296352522.md)
- [Kelun-Biotech: Buy Rating Reaffirmed as Strong sac-TMT Momentum Drives Target Price Increase from HK$507.11 to HK$642.29](https://longbridge.com/en/news/296393818.md)
- [TempraMed Announces Extension of Maccabi Healthcare Services Agreement | TMPTF Stock News](https://longbridge.com/en/news/296479419.md)
- [Rein Therapeutics releases corporate presentation on LTI-03 idiopathic pulmonary fibrosis program](https://longbridge.com/en/news/296389731.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**